With the continuous promotion of the "Healthy China 2030" strategy, the multi-level security model is becoming a new trend, and how to linkage all walks of life to help together has become the focus of attention of the industry. On September 21, Shanghai Pharmaceutical Holdings, Zhongre Life Insurance, Magnesin Health, and BCG jointly held the "Building a multi-level Medical Security System Summit Forum - and 2020 China Oncology Special Drug Payment Report Conference", and discussed the challenges and opportunities of a multi-level medical security system with 200 industry elites.
　　At the meeting, Li Yongzhong, executive director and vice president of Shanghai Medicine and general manager of Shanghai Medicine Holdings, was present and delivered a speech. "In recent years, the state has continued to promote the reform of the medical system with the" three medical linkage "as the core, and has promoted drug price reduction through various forms such as zero markup of drugs," 4+7 "volume procurement, and national medical insurance negotiations for anti-cancer drugs to reduce the burden on patients. In particular, the establishment of a super buyer such as the Medical Insurance Bureau has had a huge impact on the entire medical and pharmaceutical industry. The medical reform with payer as the core driving force has strongly promoted industrial reform, and the construction of a sustainable multi-level medical security system covering the whole people is the main line." According to Li Yongzhong, after three years of development, Shanghai Pharmaceutical investment incubated Mxin Health, has become a leader in the field of innovative medical payment, through cooperation with pharmaceutical companies, insurance and other industry parties, launched a variety of payment schemes such as pharmaceutical installment, drug benefits, commercial insurance, urban customized Huimin insurance, and actively help Chinese patients to solve payment problems.
　　At present, there are still some gaps in China's medical security system, especially in the field of tumor treatment with high treatment costs. The market for special cancer drugs is growing rapidly, while the payment power of cancer patients is relatively limited. Under the guidance of establishing a multi-level medical security system, it becomes particularly important to help payers other than basic medical insurance better relieve the payment pressure and make up the payment gap, so as to reduce the burden of patients and improve the accessibility of special cancer drugs. At the meeting, Mgxin Health, BCG and Zhongre Life Insurance jointly released the "China Cancer Special Drug Payment Report (2020) Brief edition", which analyzed the current status of cancer special drug payment from the scale of China's cancer special drug market, and made prospects and suggestions on how to support the multi-level security system for cancer special drug payment.
　　With the deepening of the medical reform, the top building of the multi-level security system has been formed, but the cohesion and coordination of all levels are still poor. Therefore, further optimization measures are still needed to promote the development of the multi-level medical security system, including strengthening the triple guarantee functions of basic medical insurance, serious illness insurance and medical assistance, and accelerating the improvement of the protection and service capabilities of commercial health insurance. Encourage other payers to participate actively. "As an important part of the social security system, the insurance and pharmaceutical industries have joined hands to actively participate in undertaking the 'healthy China' strategy and focus on the development of medical and health undertakings, which is not only an inevitable historical mission, but also an inevitable requirement for their own development." Mr. Zhang Xiaodong, CEO of Magnesium Health, said.
　　In the long run, the establishment of a multi-level security system requires the joint efforts of the government, commercial insurance companies, pharmaceutical companies, third-party service companies, associations and think tanks. The forum also gathered experts in these fields to discuss how to create a multi-level payment system. At the meeting, representatives from Shanghai Pharmaceutical Holdings, Zhongre Life Insurance, Mg Xin Health, Shanghai Chuangqi Health Development Institute, BCG, pharmaceutical companies, insurance companies and other companies also jointly proposed the establishment of a long-term communication mechanism to create a cross-industry exchange platform "Pharmaceutical insurance industry innovation alliance". The alliance can hold regular exchanges and seminars in the future, and is committed to promoting cross-industry integration and communication, and helping to build a multi-level medical security system.
　　Li Yongzhong, General Manager of Shanghai Pharma Holdings, Tian Meipan, General manager of Zhongre Life Insurance, Lu Yindi, Vice President of China Pharmaceutical Business Association, Zhang Xiaogong, CEO of Mg Health, Liu Bin, General Manager of Shanghai Pharma Cloud Health, Wu Chun, Managing Director and Global Partner of BCG, Zhou Hong, President of Roche Pharmaceuticals China, Chen Siyuan, General manager of Bristol-Myers Squibb China and Hong Kong, Head of Astrazeneca Oncology Division Fifteen guests, including Manager Yin Min, Chief Commercial Officer of Beigene Wu Qingyi, Market Access Director Qian Yun of Pfizer, and Chief Commercial Officer Jin Xiaodong of Nuocheng Jianhua, participated in the opening ceremony on stage.
　　According to the report on payment of special cancer drugs, it is estimated that at present, most of the payment of special cancer drugs in China is fully borne by patients at their own expense, followed by the medical insurance fund, and the burden ratio of other levels of protection and innovation payment is relatively low. In particular, the report puts forward many opinions on the role and role of medical insurance and commercial insurance in payers, as well as the connection with other multi-level protection perspectives, hoping to offer suggestions for building a wider range of multi-level protection from the perspective of highly representative cancer special drugs. The full report will be released in November along with the Chinese Health Insurance Blue Book series by the Academy of Social Sciences.